Mario Rizzetto

Summary

Affiliation: University of Turin
Country: Italy

Publications

  1. ncbi Prompt relapse of viremia after lamivudine discontinuation in e-minus chronic hepatitis B patients completely responders during 5 years of therapy
    Valeria Barbon
    J Hepatol 41:500-1. 2004
  2. ncbi Current management of delta hepatitis
    Mario Rizzetto
    Division of Gastroenterology, University of Torino, Torino, Italy
    Liver Int 33:195-7. 2013
  3. ncbi Epidemiology of hepatitis D
    Mario Rizzetto
    Division of Gastroenterology, University of Torino, Turin, Italy
    Semin Liver Dis 32:211-9. 2012
  4. ncbi Hepatitis D: clinical features and therapy
    Mario Rizzetto
    Department of Gastroenterology, Molinette, University of Torino, Torino, Italy
    Dig Dis 28:139-43. 2010
  5. ncbi Hepatitis D: the comeback?
    Mario Rizzetto
    Department of Gastroenterology, University of Turin, Turin, Italy
    Liver Int 29:140-2. 2009
  6. ncbi Hepatitis D: thirty years after
    Mario Rizzetto
    Division of Gastroenterology, Molinette University of Turin, Corso Bramante, Turin 10126, Italy
    J Hepatol 50:1043-50. 2009
  7. ncbi Chronic HBV-related liver disease
    Mario Rizzetto
    Gastrohepatology Department, San Giovanni Battista Hospital, University of Turin, Turin, Italy
    Mol Aspects Med 29:72-84. 2008
  8. ncbi Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study
    Chiara Giordanino
    Gastroenterology, Molinette Hospital, Turin, Italy
    Am J Gastroenterol 103:2481-7. 2008
  9. ncbi Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence
    Alfredo Marzano
    Department of Gastroenterology, San Giovanni Battista Hospital, Turin, Italy
    Liver Transpl 11:402-9. 2005
  10. ncbi Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis
    Giovanni Musso
    Department of Internal Medicine, University of Turin, Italy
    Am J Gastroenterol 100:2438-46. 2005

Detail Information

Publications101 found, 100 shown here

  1. ncbi Prompt relapse of viremia after lamivudine discontinuation in e-minus chronic hepatitis B patients completely responders during 5 years of therapy
    Valeria Barbon
    J Hepatol 41:500-1. 2004
  2. ncbi Current management of delta hepatitis
    Mario Rizzetto
    Division of Gastroenterology, University of Torino, Torino, Italy
    Liver Int 33:195-7. 2013
    ..Although the end-point of therapy is the clearance of the HBsAg, this is seldom achieved. Current management of HDV patients is based on standard practices which should be pragmatic and individualized...
  3. ncbi Epidemiology of hepatitis D
    Mario Rizzetto
    Division of Gastroenterology, University of Torino, Turin, Italy
    Semin Liver Dis 32:211-9. 2012
    ..Hepatitis D continues to ravage populations of developing and poor countries where HBV remains unchecked; action is needed to enforce HBV vaccination as effective prophylaxis not only against HBV, but against HDV as well...
  4. ncbi Hepatitis D: clinical features and therapy
    Mario Rizzetto
    Department of Gastroenterology, Molinette, University of Torino, Torino, Italy
    Dig Dis 28:139-43. 2010
    ..The problem is formidable as HDV has no enzymatic protein to be targeted by conventional antiviral therapy. A potential target of therapy is offered by the process of hepatitis D virion assembly...
  5. ncbi Hepatitis D: the comeback?
    Mario Rizzetto
    Department of Gastroenterology, University of Turin, Turin, Italy
    Liver Int 29:140-2. 2009
    ..Hepatitis D remains an important health problem outside Europe, and new foci of infection continue to be identified in developing countries...
  6. ncbi Hepatitis D: thirty years after
    Mario Rizzetto
    Division of Gastroenterology, Molinette University of Turin, Corso Bramante, Turin 10126, Italy
    J Hepatol 50:1043-50. 2009
    ..3) The search for a therapy for chronic hepatitis D (CHD). This review summarizes the progress achieved in each field of research in the thirty years that have passed since the discovery of HDV...
  7. ncbi Chronic HBV-related liver disease
    Mario Rizzetto
    Gastrohepatology Department, San Giovanni Battista Hospital, University of Turin, Turin, Italy
    Mol Aspects Med 29:72-84. 2008
    ....
  8. ncbi Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study
    Chiara Giordanino
    Gastroenterology, Molinette Hospital, Turin, Italy
    Am J Gastroenterol 103:2481-7. 2008
    ..Patients with chronic hepatitis C are at risk of developing type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG), and this risk may increase among hepatitis C virus (HCV) patients not responding to an antiviral therapy...
  9. ncbi Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence
    Alfredo Marzano
    Department of Gastroenterology, San Giovanni Battista Hospital, Turin, Italy
    Liver Transpl 11:402-9. 2005
    ..0003). In conclusion, spontaneous or antiviral-induced HBV DNA viral load at the time of surgery classifies the risk of HBV recurrence after liver transplantation and indicates the best prophylaxis strategy...
  10. ncbi Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis
    Giovanni Musso
    Department of Internal Medicine, University of Turin, Italy
    Am J Gastroenterol 100:2438-46. 2005
    ..Our findings provide further rationale for therapeutic approaches aimed at increasing adiponectin levels together with restoring beta-cell function and insulin sensitivity...
  11. ncbi Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
    Rinaldo Pellicano
    Department of Gastro Hepatology, San Giovanni Battista Molinette Hospital, Torino, Italy
    J Med Virol 80:628-31. 2008
    ..49; 95% CI: 0.28-0.85). Serum uric acid level > or =5.8 mg/dl is predictive of poor response to HCV treatment. Prospective studies are needed to clarify the issue...
  12. ncbi Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study
    Chiara Giordanino
    Division of Gastroenterology, University of Turin, San Luigi Medical School, Orbassano, Italy
    Dig Liver Dis 44:406-12. 2012
    ....
  13. ncbi A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
    Elisabetta Bugianesi
    Department of Gastroenterology, University of Turin, Italy
    Am J Gastroenterol 100:1082-90. 2005
    ..Limited histological data support an association between improved aminotransferases and biopsy findings, which require confirmation in a double-blind trial with appropriate statistical power based on liver histology...
  14. ncbi Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?
    Alessia Ciancio
    Dipartimento di Gastroenterologia, Ospedale Molinette, Torino, Italy
    Am J Gastroenterol 101:1811-6. 2006
    ....
  15. ncbi The first one thousand liver transplants in Turin: a single-center experience in Italy
    Mauro Salizzoni
    Liver Transplantation Center, San Giovanni Battista Hospital, Turin, Italy
    Transpl Int 18:1328-35. 2005
    ..76% at 5 years respectively). Increasing experience in liver transplant surgery and postoperative care allowed standardization of the procedure and expansion of the activity, with parallel improvement of the results...
  16. ncbi The natural history of gastrointestinal subepithelial tumors arising from muscularis propria: an endoscopic ultrasound survey
    Mauro Bruno
    Department of Gastro Hepatology, Molinette Hospital, Torino, Italy
    J Clin Gastroenterol 43:821-5. 2009
    ..Aim of this study was to evaluate the natural course of benign-appearing lesions originating from muscularis propria in organs where GISTs significantly overcome leiomyomas...
  17. ncbi Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants
    Alfredo Marzano
    Department of Gastroenterology, San Giovanni Battista Hospital, Turin, Italy
    Liver Transpl 11:532-8. 2005
    ....
  18. ncbi Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
    Ester Vanni
    Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, Turin, Italy
    Hepatology 50:697-706. 2009
    ..Substrate competition by increased lipid oxidation and possibly enhanced hepatic expression of inflammatory cytokines/mediators could be involved in the defective glucose regulation...
  19. ncbi Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study
    Carlo Alessandria
    Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital University of Turin, Turin, Italy
    Dig Liver Dis 43:881-6. 2011
    ..Albumin infusion (8g of albumin/L of ascites removed) is effective in preventing it, but high costs and scant availability limit its use...
  20. ncbi Ectopic liver and hepatocarcinogenesis: report of three cases with four years' follow-up
    Nicola Leone
    Department of Gastroenterology, Division of B Surgery and First Service of Human Pathology, Molinette Hospital, Turin, Italy
    Eur J Gastroenterol Hepatol 16:731-5. 2004
    ..The patients were followed up for 4 years after surgery: two remain free of disease, suggesting that the unique localisation and growth pattern may render these tumours particularly susceptible to curative resection...
  21. ncbi Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment
    Antonio DʼAvolio
    Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Italy
    Ther Drug Monit 34:165-70. 2012
    ..However, no definitive data are yet available on the role of plasma RBV concentrations on hemoglobin (Hb) decrement. Moreover, no data have been published on the possible interplay between these 2 factors...
  22. ncbi Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta
    Grazia Anna Niro
    Gastroenterology CSS Hospital, S Giovanni Rotondo, and Gastroenterology Molinette Hospital and Unversity, Turin, Italy
    Hepatology 44:713-20. 2006
    ..Overall tolerance of therapy was poor...
  23. ncbi A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy
    Giorgio Saracco
    Dipartimento di Gastroenterologia, Ospedale Molinette, Torino, Italy
    Hepatology 36:959-66. 2002
    ....
  24. ncbi Fatal multiple systemic embolisms after injection of cyanoacrylate in bleeding gastric varices of a patient who was noncirrhotic but with idiopathic portal hypertension
    Giorgio Saracco
    Department of Gastroenterology, Molinette Hospital, Torino, Itlay
    Gastrointest Endosc 65:345-7. 2007
  25. ncbi The practice of percutaneous liver biopsy in a gastrohepatology day hospital: a retrospective study on 835 biopsies
    Giovanni Clemente Actis
    Department of Gastro Hepatology and Clinical Nutrition, San Giovanni Battista Molinette Hospital, Torino, 10126, Italy
    Dig Dis Sci 52:2576-9. 2007
    ..In conclusion, these data accord with indications expressed by international guidelines. The impact of liver biopsy on therapeutic decision-making needs to be studied further...
  26. ncbi Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver
    Elisabetta Bugianesi
    Division of Gastro Hepatology, Department of Internal Medicine, University of Turin, Turin, Italy
    Hepatology 39:179-87. 2004
    ..Increased ferritin levels are markers of severe histologic damage, but not of iron overload. Iron burden and HFE mutations do not contribute significantly to hepatic fibrosis in the majority of patients with NAFLD...
  27. ncbi The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis
    Giovanni C Actis
    Department of Digestive Disease and Nutrition, Ospedale Molinette, c so Bramante 88, Torino, Italy
    Biomed Pharmacother 63:362-5. 2009
    ..By contrast, the toxicity rates were higher than expected. Failure to genotype or to use escalating AZA doses can only be hypothesized as causes...
  28. ncbi Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension
    Chiara Elia
    Department of Gastrohepatology, San Giovanni Battista Hospital, Corso Bramante 88, Turin, Italy
    Eur J Gastroenterol Hepatol 23:573-7. 2011
    ..We also prospectively evaluated portal pressure by hepatic venous portal gradient (HVPG) before and within 3 days by TACE in a group of 15 patients...
  29. ncbi Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy
    Giorgio Palestro
    Department of Oncology, University of Torino, 10126 Torino, Italy
    World J Gastroenterol 11:7131-5. 2005
    ....
  30. ncbi Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance
    Valeria Ghisetti
    Laboratory of Microbiology, Molinette Hospital, Turin, Italy
    Liver Transpl 10:356-62. 2004
    ....
  31. ncbi Outcome of chronic delta hepatitis in Italy: a long-term cohort study
    Grazia Anna Niro
    Division of Gastroenterology, Casa Sollievo Sofferenza Hospital, IRCCS, San Giovanni, Rotondo, Italy
    J Hepatol 53:834-40. 2010
    ..To investigate the impact of HDV infection on morbidity and mortality of patients...
  32. ncbi Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment
    Antonio D'Avolio
    Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
    Ther Drug Monit 34:722-8. 2012
    ..The aim of our study was to carry out an integrated analysis of the effects of polymorphisms and ribavirin (RBV) plasma exposure on outcome...
  33. ncbi Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis
    Silvia Gaia
    San Giovanni Battista Hospital, Gastroenterology, C Bramante 88 10128, Italy
    J Hepatol 54:64-71. 2011
    ....
  34. ncbi Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis
    Elisabetta Bugianesi
    Gastroenterology Department, University of Turin, Italy
    Hepatology 44:1648-55. 2006
    ..Virus-induced hepatic steatosis as seen in CHC-3 does not contribute significantly to liver fibrosis...
  35. ncbi Preliminary experience with a new cytology brush in EUS-guided FNA
    Mauro Bruno
    Department of Gastro Hepatology, Molinette Hospital, Torino, Italy
    Gastrointest Endosc 70:1220-4. 2009
    ..Recently, the EchoBrush (Cook Endoscopy, Winston-Salem, NC), a disposable cytologic brush, was introduced to the market. To date, only 1 study, limited to 10 pancreatic cyst cases, using this device has been published...
  36. ncbi Ectopic livers and related pathology: report of three cases of benign lesions
    Nicola Leone
    Department of Gastroenterology, Molinette Hospital, Turin, Italy
    Dig Dis Sci 50:1818-22. 2005
  37. ncbi Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study
    Wilma Debernardi Venon
    Department of Gastroenterology, Ospedale Molinette, S Giovanni Battista Hospital, c so Bramante 88, 10126, Turin, Italy
    J Hepatol 38:455-60. 2003
    ..We tested the efficacy of Irbesartan (Irb) vs. Propranolol (Pro) in reducing portal pressure and evaluated its systemic haemodynamic effects...
  38. ncbi Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity
    Elisabetta Bugianesi
    Division of Gastroenterology, University of Turin, Ospedale San Giovanni Battista, Corso Bramante 88, I 10126 Torino, Italy
    J Clin Endocrinol Metab 90:3498-504. 2005
    ..Hypoadiponectinemia in NAFLD is part of a metabolic disturbance characterized by ectopic fat accumulation in the central compartment...
  39. ncbi Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy
    Gian Paolo Caviglia
    Department of Internal Medicine, University of Turin, Turin, Italy
    Hepat Mon 12:e7292. 2012
    ..The impact of OBI in patients with chronic hepatitis C (CHC) is still unclear...
  40. ncbi Pancreatic cancer imaging: the new role of endoscopic ultrasound
    Claudio De Angelis
    Gastrohepatology Department, San Giovanni Battista Hospital, University of Turin Turin, Italy
    JOP 8:85-97. 2007
    ..In the near future, there will be great opportunities for the development of diagnostic and therapeutic EUS and pancreatic cancer could be the best testing ground...
  41. ncbi Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor
    Paola Manzini
    SCDO SIMT Banca del Sangue and SCDU Gastro epatologia, AOU S Giovanni Battista, Corso Bramante 88, Turin, Italy
    Transfusion 49:757-64. 2009
    ..Preliminary evidence of cases of acute occult hepatitis B virus (HBV) infection (OBI) has been recently reported in the literature. Furthermore, OBI definition has been the object of an international consensus conference...
  42. ncbi Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment
    Carlo Alessandria
    Department of Gastroenterology and Department of Clinical Nutrition, San Giovanni Battista Hospital, Torino, Italy
    Eur J Gastroenterol Hepatol 16:607-12. 2004
    ..Further studies are needed to confirm this finding and ultimately to assess a correction factor to better predict survival after TIPS in patients with functional renal impairment...
  43. ncbi Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?
    Giovanni Sansoè
    Gastroenterology Unit, Gradenigo Hospital, Turin, Italy
    J Hepatol 43:791-8. 2005
    ..We determined the effects of NEP inhibition by candoxatrilat on hormonal status, liver function and arterial and portal pressures in rats with CCl4-induced cirrhosis...
  44. ncbi AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers
    Wilma Debernardi-Venon
    Division of Gastroenterology and Hepatology, S Giovanni Battista Hospital, Turin, Italy
    J Hepatol 46:1026-33. 2007
    ..To examine the long-term effects of Candesartan cilexetil, an angiotensin type 1 (AT1) receptor blocker, on portal-systemic haemodynamics and on liver fibrosis...
  45. ncbi Lack of association between seroprevalence of Helicobacter pylori infection and primary biliary cirrhosis
    Marilena Durazzo
    Department of Internal Medicine, University of Turin, Corso A M Dogliotti 14, 10126 Turin, Italy
    World J Gastroenterol 10:3179-81. 2004
    ..To determine the association between seroprevalence of Helicobacter pylori (H pylori) infection and primary biliary cirrhosis (PBC)...
  46. ncbi Helicobacter species and liver diseases: association or causation?
    Rinaldo Pellicano
    Department of Gastro Hepatology, Molinette Hospital, Turin, Italy
    Lancet Infect Dis 8:254-60. 2008
    ..More studies are therefore needed to confirm whether a causal association exits between the presence of Helicobacter spp in the liver and the development of cirrhosis and hepatocellular carcinoma...
  47. ncbi Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease
    Daniele Simondi
    Department of Gastrohepatology, San Giovanni Battista Hospital of Turin, Turin, Italy
    Inflamm Bowel Dis 14:645-51. 2008
    ..The objective of the study was to evaluate the diagnostic accuracy of recently developed antiglycan serological tests in clinical practice for the diagnosis of Crohn's disease...
  48. ncbi Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation
    Luisa Giaccone
    Division of Hematology, SGB Hospital, University of Torino, Torino, Italy
    Biol Blood Marrow Transplant 16:809-17. 2010
    ....
  49. ncbi Loss of tubuloglomerular feedback in decompensated liver cirrhosis: physiopathological implications
    Giovanni Sansoè
    Gradenigo Hospital, Torino, Italy
    Dig Dis Sci 50:955-63. 2005
    ....
  50. ncbi Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection
    Rinaldo Pellicano
    U.O.A.D.U. Gastro-Hepatology, Hospital S Giovanni Battista (Molinette, Torino, Italy
    Eur J Gastroenterol Hepatol 14:1377-82. 2002
    ..However, the results of the trial do not support the use of IFN-beta monotherapy in patients with chronic hepatitis C that is resistant to IFN-alpha...
  51. ncbi Prevalence of non-organ-specific autoantibodies in patients suffering from duodenal ulcer with and without Helicobacter pylori infection
    Rinaldo Pellicano
    UOADU Gastro Hepatology, Molinette Hospital, Turin, Italy
    Dig Dis Sci 49:395-8. 2004
    ..9%), SMA in 3 of 38 (7.9%), and anti-LKM-1 in 0 patients. The difference was not statistically significant. In this population, H. pylori infection is not associated with an increased prevalence of NOSAs...
  52. ncbi Clinical impact of A/H1/N1/09 influenza in patients with cirrhosis: experience from a nosocomial cluster of infection
    Alfredo Marzano
    Gastro Hepatology Unit, San Giovanni Battista Hospital, University of Turin, Turin, Italy
    J Med Virol 85:1-7. 2013
    ..Vaccination, preventive and early treatment and a strict control of nosocomial spread should be activated carefully in patients with cirrhosis during epidemics influenza...
  53. ncbi Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine
    Mario Rizzetto
    Department of Gastroenterology, University of Turin, Molinette Hospital, Corso Bramante 88, 10125 Turin, Italy
    J Hepatol 39:S168-71. 2003
  54. ncbi HDV: thirty years later
    Antonina Smedile
    Gastroenterology and Hepatology Division University of Torino, San Giovanni Battista Hospital, Torino, Italy
    Dig Liver Dis 43:S15-8. 2011
    ..Hepatitis D remains a major health problem in many developing areas with outbreaks of the disease continuing to be reported from Asia, Africa and South Africa...
  55. ncbi Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial
    Franco Brunello
    Divisione di Gastro Epatologia, Ospedale San Giovanni Battista di Torino, Turin, Italy
    Scand J Gastroenterol 43:727-35. 2008
    ....
  56. ncbi Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation
    Alessandro Musso
    Division of Gastroenterology, Ospedale San Giovanni Battista, University of Torino, Torino, Italy
    Inflamm Bowel Dis 11:91-8. 2005
    ....
  57. ncbi Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin
    Bruna Lavezzo
    Department of Gastroenterology, Molinette Hospital, C.so Bramante 88, 10126 Turin, Italy
    J Hepatol 37:247-52. 2002
    ..CONCLUSIONS: CT is efficacious in controlling HCV disease in about 20% of transplants with recurrent hepatitis C. Six months of therapy are as efficacious as 12 months...
  58. ncbi Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus
    Alessia Ciancio
    Ospedale Molinette, Banca del Sangue e del Plasma della città di Torino, Torino, Italy
    Ann Intern Med 142:903-9. 2005
    ..The potential role of digestive endoscopy as a mode for transmission of hepatitis C virus (HCV) is controversial...
  59. ncbi Serum heat shock protein 27 levels in patients with hepatocellular carcinoma
    Gabriella Gruden
    Department of Medical Science, University of Turin, C so AM Dogliotti 14, 10126 Turin, Italy
    Cell Stress Chaperones 18:235-41. 2013
    ..5 pg/ml) for differentiating patients with HCC from those with HCC-free chronic liver disease were 70 and 73 %, respectively. In conclusion, sHsp27 levels are enhanced in patients with HCC and may represent a candidate biomarker of HCC...
  60. ncbi Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions
    Paola Rita Brunocilla
    Division of Gastroenterology and Hepatology, AO San Giovanni Battista, Turin, Italy
    Med Oncol 30:345. 2013
    ..3 (range -60.1 to 17.9; P = 0.0003). Treatment withdrawal from adverse events was higher than previously reported, significant QoL decrease occurred, and estimated feasibility was 66.7 %...
  61. ncbi Safety and efficacy of endoscopic retrograde cholangiopancreatography in patients with post-liver transplant biliary complications: results of a cohort study with long-term follow-up
    Claudia Sanna
    Department of Gastroenterology, University of Turin, Molinette Hospital, Turin, Italy
    Gut Liver 5:328-34. 2011
    ..This study was performed to evaluate the safety and long-term efficacy of ERCP in transplant patients...
  62. ncbi Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures
    Alessandro Repici
    Department of Gastroenterology and Clinical Nutrition, Molinette Hospital, Torino, Italy
    Gastrointest Endosc 60:513-9. 2004
    ....
  63. ncbi Acute small-bowel perforation secondary to capsule endoscopy
    Alessandro Repici
    Rozzano (Milano, Torino, Italy
    Gastrointest Endosc 67:180-3. 2008
  64. ncbi Epithelial microchimerism: consistent finding in human liver transplants
    Silvia Gaia
    Department of Gastroenterology, San Giovanni Battista Hospital, Turin, Italy
    J Gastroenterol Hepatol 21:1801-6. 2006
    ....
  65. ncbi Insulated-tip knife endoscopic mucosal resection of large colorectal polyps unsuitable for standard polypectomy
    Alessandro Repici
    Department of Gastroenterology, IRCCS Istituto Clinico Humanitas, Milano, Italy
    Am J Gastroenterol 102:1617-23. 2007
    ..This study was conducted to evaluate the safety and efficacy in obtaining en bloc resection with It-knife EMR of large colonic lesions not resectable with standard endoscopic techniques...
  66. ncbi Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort
    Andrea Marengo
    Gastro Hepatology Unit, San Giovanni Battista Hospital, University of Turin, Italy
    Antivir Ther 18:87-94. 2013
    ....
  67. ncbi An aggressive medical approach for inflammatory bowel disease: clinical challenges and therapeutic profiles in a retrospective hospital-based series
    Giovanni C Actis
    Division of Gastroenterology, Ospedale Molinette, Torino, Italy
    Curr Clin Pharmacol 7:209-13. 2012
    ..We studied the toxicity of cyclosporin (CsA), azathioprine, and mesalamine in 94 patients with inflammatory bowel disease (IBD)...
  68. ncbi Detection of serum HDV RNA by RT-PCR
    Antonina Smedile
    Department of Gastroenterology, University of Torino, Azienda Ospedaliera S. Giovanni, Battista, Italy
    Methods Mol Med 95:85-93. 2004
  69. ncbi Appropriateness of colonoscopy in a digestive endoscopy unit: a prospective study using ASGE guidelines
    Renzo Suriani
    Department of Gastroenterology, Ospedale degli Infermi, Rivoli, Italy
    J Eval Clin Pract 15:41-5. 2009
    ....
  70. ncbi Efficacy of lamivudine in HBeAg-negative chronic hepatitis B
    Mario Rizzetto
    Department of Gastroenterology, Molinette, University of Torino, Torino, Italy
    J Med Virol 66:435-51. 2002
    ..Extended lamivudine treatment beyond 2 years is an option, but further investigation is required to define stopping criteria and the impact of YMDD variants...
  71. ncbi Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2
    Carlo Alessandria
    Department of Gastroenterology, San Giovanni Battista Hospital, Torino, Italy
    Eur J Gastroenterol Hepatol 14:1363-8. 2002
    ....
  72. ncbi Spectral electroencephalogram analysis in hepatic encephalopathy and liver transplantation
    Alessia Ciancio
    Department of Gastroenterology, University of Torino and San Giovanni Battista Hospital, Turin, Italy
    Liver Transpl 8:630-5. 2002
    ..The improvement in (S)EEG results observed in transplant recipients confirms the reversibility of bioelectric brain dysfunction with restoration of liver functions...
  73. ncbi Capsule enteroscopy vs. other diagnostic procedures in diagnosing obscure gastrointestinal bleeding: a cost-effectiveness study
    Riccardo Marmo
    Division of Gastroenterology, L Curto Hospital, Polla, Sant Arsenio, Italy
    Eur J Gastroenterol Hepatol 19:535-42. 2007
    ..The costs of capsule enteroscopy examination, however, make it uncertain whether the clinically relevant diagnostic gain is also associated with cost savings...
  74. ncbi Progress in the prevention and control of viral hepatitis type B: closing remarks
    Mario Rizzetto
    Department of Gastroenterology, University of Torino, Torino, Italy
    J Med Virol 67:463-6. 2002
    ..Efforts to sustain immunization programs and to make vaccines and drugs available to countries with limited resources, are the main challenges to the eradication of hepatitis B in the next few decades...
  75. ncbi Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background: a case report
    Giovanni C Actis
    Department of Gastroenterology, Ospedale Molinette, Corso Bramante 88, 10126 Torino, Italy
    Mt Sinai J Med 72:136-40. 2005
    ..The implications of the case are discussed...
  76. ncbi Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
    Elisabetta Bugianesi
    Department of Gastroenterology, Ospedale S Giovanni Battista, University of Turin, Turin, Italy
    Gastroenterology 123:134-40. 2002
    ..Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis; whether NASH plays also a role in the development of hepatocellular carcinoma (HCC) is unknown...
  77. ncbi Identification of HBV DNA sequences that are predictive of response to lamivudine therapy
    Alessia Ciancio
    Georgetown University Medical Center, Division of Molecular Virology and Immunology, Rockville, MD, USA
    Hepatology 39:64-73. 2004
    ..Furthermore, at least in HBeAg-negative patients infected predominantly with HBV genotype D, specific viral DNA sequences which are present before therapy appear to be useful as predictors of long-term response to lamivudine treatment...
  78. ncbi Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    N Engl J Med 352:2673-81. 2005
    ..We evaluated the effect of continued therapy as compared with cessation of therapy...
  79. ncbi Helicobacter pylori seroprevalence in patients with cirrhosis of the liver and hepatocellular carcinoma
    Nicola Leone
    Department of Gastro-Hepatology, Molinette Hospital, Via Chiabrera 34, 10126 Turin, Italy
    Cancer Detect Prev 27:494-7. 2003
    ..05); 11 out of 16 (68.7%) female patients were seropositive versus 9 out of 16 (56.2%) control subjects (P=n.s.). CONCLUSION: Seroprevalence of antibodies to H. pylori was found to be higher in patients with HCC than in controls...
  80. ncbi Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    N Engl J Med 348:800-7. 2003
    ..Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials...
  81. ncbi Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation
    Elisabetta Cerutti
    Department of Anesthesiology and Intensive Care, University of Turin, Turin, Italy
    Liver Transpl 10:289-94. 2004
    ..TEG monitoring could be useful in the perioperative management of donors to guide antithrombotic treatment and increase the safety of the procedure...
  82. ncbi Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006)
    Didier Samuel
    HepatoBiliary Centre, Inserm-Paris XI U 785, Paul Brousse Hospital, APHP, Villejuif, France
    J Hepatol 45:127-43. 2006
  83. ncbi A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients
    Ting Tsung Chang
    National Cheng Kung University Medical College, Tainan, Taiwan
    Gastroenterology 129:1198-209. 2005
    ..This randomized, dose-ranging, phase 2 study compared the efficacy and safety of entecavir with lamivudine in lamivudine-refractory patients...
  84. ncbi Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Gastroenterology 131:1743-51. 2006
    ..We investigated the efficacy, safety, and resistance profile of adefovir dipivoxil treatment for up to 240 weeks...
  85. ncbi Italian blood donors with anti-HBc and occult hepatitis B virus infection
    Paola Manzini
    Banca del Sangue e del Plasma, A O S Giovanni Battista di Torino, Corso Bramante 88, 10126 Torino, Italy
    Haematologica 92:1664-70. 2007
    ..The aim of our study was to evaluate the actual prevalence, viral load and genotype of occult HBV infections among first-time blood donors in north-western Italy and to suggest a way to minimize risks of transmission of this infection...
  86. ncbi Definition of hepatitis B infection for the best practice in chronic disease and in immunosuppressed patients
    Alfredo Marzano
    J Hepatol 48:515-6; author reply 516. 2008
  87. ncbi Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B
    Mario Rizzetto
    Experimental Department of Gastroenterology, San Giovanni Battista Hospital C So Bramante, 88 10126 Turin, Italy
    J Hepatol 42:173-9. 2005
    ..The histological and clinical outcome of lamivudine 100mg/day was assessed in 76 HBeAg-negative chronic hepatitis B patients previously randomised to a double-blind comparison study of lamivudine and placebo...
  88. ncbi Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine
    Silvia Gaia
    Department of Gastroenterology and Hepatology, ASO San Giovanni Battista, c so Bramante 88, 10126 Turin, Italy
    J Hepatol 48:540-7. 2008
    ..In lamivudine-resistant patients with chronic hepatitis B (CHB), we compared efficacy, predictive response factors and changes in viral mutants in two antiviral approaches with adefovir...
  89. ncbi Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
    Vito Di Marco
    Cattedra e U O C di Gastroenterologia, Clinica Medica, Universita di Palermo, Palermo, Italy
    Hepatology 40:883-91. 2004
    ..After 4 years of therapy, 39% of patients maintain a virological and biochemical response. Loss of virological response may lead to clinical deterioration in patients with cirrhosis...
  90. ncbi Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study
    Giovanni B Gaeta
    Department of Medicine and Public Health, Unit of Infectious Diseases, Second University of Naples, Via Cotugno, 1 C O Osp Gesù e Maria, 80135 Naples, Italy
    J Hepatol 39:1036-41. 2003
    ..This study assess prevalence, risk factors, and clinical and virological features of dual hepatitis B virus (HBV)/hepatitis C virus (HCV) infection...
  91. ncbi Response-guided therapy: optimizing treatment now and in the future
    Patrick Marcellin
    Antivir Ther 13:1-2. 2008
  92. ncbi Inactive hepatitis B virus carriers: a favourable clinical condition
    Silvia Gaia
    Eur J Gastroenterol Hepatol 17:1435-6. 2005
  93. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  94. ncbi Ineffectiveness of hepatitis B vaccination in lamivudine-treated cirrhotics
    Elena Gentilcore
    J Hepatol 40:357-8. 2004
  95. ncbi Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study
    Gianpiero Benetti
    Section of Hepatology, Division of Medicine, Predabissi Hospital, Melegnano MI, Italy
    Intern Emerg Med 1:113-8. 2006
    ..The treatment of patients with hepatitis C virus (HCV) genotype 1 infection remains disappointing...
  96. ncbi Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's disease
    Francesca Bresso
    Strategic Research Center IRIS, Karolinska Institutet, Stockholm, Sweden
    Inflamm Bowel Dis 13:531-6. 2007
    ..Given the important biological functions of CFTR in the intestine, we tested whether this mutation is of relevance to IBD...
  97. ncbi Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates
    Nereo Segnan
    Centro Prevenzione Oncologica Regione Piemonte and Azienda Sanitaria Ospedaliera S Giovanni Battista, Torino, Italy
    J Natl Cancer Inst 97:347-57. 2005
    ..We compared the participation and detection rates achievable through different strategies of colorectal cancer screening...
  98. ncbi Helicobacter pylori and coronary artery disease: which is the better target population?
    Rinaldo Pellicano
    Dig Dis Sci 52:3041-2. 2007
  99. ncbi Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin
    Mario Rizzetto
    J Hepatol 42:275-6; author reply 276-7. 2005
  100. ncbi Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
    Giulio Marchesini
    Unit of Metabolic Diseases and Department of Internal Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy
    Hepatology 37:917-23. 2003
    ..The increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades...
  101. ncbi Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma
    Rinaldo Pellicano
    Ambulatorio di Gastroenterologia, Ospedale S Giovanni Battista, Via Chiabrera 34, III piano, 10126 Torino, Italy
    World J Gastroenterol 10:598-601. 2004
    ..CONCLUSION: Helicobacter spp., carcinogenic in mice, were found at a higher frequency in the liver of patients with HCV-related cirrhosis and HCC than those in patients without primary liver disease...